Dysregulation of neurotrophic and haematopoietic growth factors in Alzheimer's disease: from pathophysiology to novel treatment strategies

Curr Alzheimer Res. 2014 Jan;11(1):27-39. doi: 10.2174/1567205010666131120100743.

Abstract

Alzheimer's disease (AD) is the leading cause of dementia in the elderly. Growth factors have been demonstrated to act in a synergistic way in angiogenesis and neurogenesis contributing to self-healing powers of the adult human brain. A growing body of evidence demonstrates that levels of many growth factors (neurotrophins and hematopoietins) are altered in cerebrospinal fluid and peripheral blood from AD patients and in animal models of AD. The present review summarizes the role of several neurotrophic growth factors (e.g., BDNF, SCF, NGF, GDNF) and haematopoietic growth factors (e.g., G-CSF, VEGF, SDF-1) in AD. Moreover, we summarize recent studies evaluating the diagnostic and prognostic value of growth factor levels in blood and cerebrospinal fluid in patients with AD and discuss the potential role of these growth factors as a promising new therapeutic approach in AD.

Publication types

  • Review

MeSH terms

  • Alzheimer Disease / drug therapy
  • Alzheimer Disease / physiopathology*
  • Animals
  • Blood-Brain Barrier / drug effects
  • Blood-Brain Barrier / physiopathology
  • Brain / blood supply
  • Brain / drug effects
  • Brain / physiopathology
  • Hematopoietic Cell Growth Factors / metabolism*
  • Hematopoietic Cell Growth Factors / therapeutic use
  • Humans
  • Nerve Growth Factors / metabolism*
  • Nerve Growth Factors / therapeutic use
  • Neurogenesis / drug effects
  • Neurogenesis / physiology

Substances

  • Hematopoietic Cell Growth Factors
  • Nerve Growth Factors